Introduction
Neuronal dysfunction in Alzheimer's disease (AD) is related to accumulation of soluble oligomers of the amyloid-␤ peptide (A␤Os; Lambert et al., 1998; Ferreira and Klein, 2011; Mucke and Selkoe, 2012) . Interaction of these toxic particles with several distinct types of receptors in neurons (Wang et al., 2000; Xie et al., 2002; Laurén et al., 2009; triggers glutamate excitotoxicity, synaptic dysfunction, inhibition of long-term potentiation (LTP), and neuronal death (Querfurth and LaFerla, 2010; Paula-Lima et al., 2013) . The exact mechanisms underlying each of these effects are not fully understood, but toxic actions of A␤Os seem to depend, at least in part, on the cellular prion protein (PrP C ; Laurén et al., 2009; Bate and Williams, 2011; Kudo et al., 2012) . PrP C is a master regulator of cellular signaling , likely by scaffolding distinct ligands and neuronal transmembrane receptors Santos et al., 2013) . Interaction of A␤O with the PrP C region comprising amino acid residues 95-105 appears critical for neuronal toxicity (Laurén et al., 2009; Chung et al., 2010; Barry et al., 2011; Freir et al., 2011) . Accordingly, disrupting A␤O binding to PrP C seems to alleviate PrP C -dependent A␤O toxicity. For example, antibodies targeting PrP C prevent synaptic plasticity deficits induced by A␤Os (Chung et al., 2010; Barry et al., 2011; Freir et al., 2011) . However, PrP C antibodies can lead to toxicity by triggering neuronal signaling (Solforosi et al., 2004) .
Therefore, endogenous physiological ligands of PrP C may provide an alternative means of modulating A␤O-induced toxicity.
Stress-inducible phosphoprotein 1 (STI1) is a cochaperone secreted by astrocytes that can interact with and signal via PrP C (Zanata et al., 2002; Lopes et al., 2005; Lima et al., 2007; Caetano et al., 2008; . STI1 binds to PrP C at residues 113-128 (Chiarini et al., 2002; Zanata et al., 2002) , adjacent to the A␤O binding site, leading to reciprocal conformational changes in both proteins (Romano et al., 2009) . Extracellular STI1 forms a signaling complex with PrP C in hippocampal neurons that promotes calcium influx through ␣7 nicotinic acetylcholine receptors (␣7nAChR; ). This in turn triggers several signaling pathways that protect neurons from apoptosis (Lopes et al., 2005; Caetano et al., 2008; . Importantly, both PrP C and ␣7nAChR are recognized targets of A␤ peptides (Wang et al., 2000 Magdesian et al., 2005; Laurén et al., 2009; Um et al., 2012) . Interestingly, recent system biology approaches have implicated differential expression of the STI1 gene (STIP1) in AD (Zhang et al., 2013) . Moreover, a loss-of-function STI1 mutation increases Tau toxicity in a fly model of tauopathy (Ambegaokar and Jackson, 2011) .
Here, we provide evidence supporting a role for STI1-regulated pathways in AD. We find that STI1 inhibited A␤O binding to PrP and to cells expressing PrP C . In addition, toxic effects mediated by A␤O could be prevented by STI1 in a PrP C and ␣7nAChR-dependent way. Our results suggest that altered levels of STI1 in individuals with AD may influence A␤O-induced neuronal toxicity.
Materials and Methods

Mouse lines. Genetically modified STI1
Ϫ/ϩ mice were generated by standard homologous recombination techniques (Prado et al., 2006) , using C57BL/6j ES cells, as described previously . In mammals, elimination of STI1 causes early embryonic lethality; hence, STI1 Ϫ/ϩ neurons were used here . Prnp Ϫ/Ϫ mice in a C57BL/6j background were kindly donated by Dr. Frank Jirik (University of Calgary, Calgary, Alberta, Canada) (Tsutsui et al., 2008) . APPswe/ PS1dE9 (Jankowsky et al., 2001 ) and ␣7nAChR Ϫ/Ϫ (Orr-Urtreger et al., 1997) mice in a C57BL/6j background were obtained from The Jackson Laboratory. Procedures were conducted in accordance with approved animal use protocols at the University of Western Ontario (2008/127) and the A. C. Camargo Hospital (037/09) following Canadian Council of Animal Care and National Institutes of Health guidelines.
Preparation of proteins and peptides. Recombinant mouse PrP with an N-terminal His tag was produced in Escherichia coli strain BL21(DE3). For this, bacteria were transformed with pRSET/PrP plasmid DNA kindly provided by Prof. Kurt Wüthrich (ETH Zürich, Zürich, Switzerland). PrP was expressed in inclusion bodies that were solubilized in 8 M urea and 20 mM Tris-HCl, pH 8.0, and purified using Ni 2ϩ -affinity chromatography. After that, PrP was refolded by dialysis against 10 mM NaOAc, 10 mM 2-mercaptoethanol, and 1 mM EDTA, pH 5.0, and stored for Ͻ10 d at 4°C. Recombinant mouse PrP(112-231) peptide was provided by the PrP 5 PrioNet facility (University of Alberta, Edmonton, Canada). Recombinant STI1 was produced as a (His) 6 -SUMO-tag-fused protein by cloning STI1 cDNA into pE-SUMO vector (Lifesensors) and transforming E. coli strain BL21(DE3) with the obtained pE-SUMO-STI1 plasmid DNA. After initial purification using Ni 2ϩ -affinity chromatography, the (His) 6 -SUMO tag was cleaved off using SUMO Pro enzyme (Lifesensors), and untagged STI1 was obtained by a second Ni 2ϩ -affinity purification step. Pure STI1 was stored for less than a week at 4°C or fast-frozen in liquid nitrogen and stored at Ϫ80°C for 1-2 months. TPR2A and its 230 -245 amino acid deletion variant (TPR2A⌬ 230 -245 ) were produced as N-terminal His-tag constructs in E. coli strain BL21(DE3) transformed with pDEST17 vector (Invitrogen) containing the correspondent gene. After cleavage with His-TEV protease, (His) 6 tag and the protease were removed by Ni 2ϩ -affinity purification, and the untagged peptides were stored for Ͻ10 d at 4°C. Quality of protein preparations, including Hsp90 (Cayman Chemical) and lysozyme (SigmaAldrich), was routinely checked using 4 -20% SDS-PAGE gels (Lonza) stained for protein bands with RapidStain reagent (EMD Millipore), which allows 100 ng resolution. Circular dichroism (CD) spectra measured as described previously (Ostapchenko et al., 2008) were used to assess the quality of recombinant proteins. The presence of lipopolysaccharides in protein preparations was tested using ToxinSensor Endotoxin Assay Kit (GenScript); no more than 0.2 endotoxin units (EU) of E. coli endotoxin equivalent was present in our preparations. A␤Os were prepared from A␤ 1-42 peptide (rPeptide) similarly to a previously described procedure (Caetano et al., 2011) . Briefly, the peptide was monomerized in hexafluoroisopropanol, dried in a SpeedVac centrifuge, restored in DMSO to 1 mM solution, and diluted in PBS (CD and LTP experiments) or F-12 medium (all other experiments) to the final concentration of 100 M (hereafter monomer concentration used as A␤O concentration). After incubation for 24 h at 4°C, A␤Os were cleared by centrifugation when needed and either used immediately or stored at Ϫ80°C for no more than a few weeks. Peptide preparation quality was checked by several methods. Western blot with 6E10 (1:2000; Covance) antibody was done by a standard technique after peptide separation on 13.5% Tris-tricine SDS-PAGE and electrotransfer to polyvinyl difluoride membrane. CD spectra were obtained from 25 M A␤O using a J810 spectropolarimeter (Jasco) equipped with a 1 mm cuvette, with five scans averaged for each resulting spectra. Size-exchange chromatography was done using Ä KTA-FPLC (GE Healthcare) equipped with a Superdex 75 column (GE Healthcare) following the procedure described previously (Larson et al., 2012) . For atomic force microscopy (AFM), A␤O preparations were diluted to 0.1 M, deposited on a freshly cleaved piece of mica for 10 min, and dried under a nitrogen stream. Images were acquired in tapping mode using a Cypher AFM (Asylum Research) mounted with silicon tips (AC160TS; from Olympus; nominal spring constant of 40 N/m). Section analyses were performed using the AFM software to determine the height of the species imaged. Their corresponding molecular weight was determined via a calibration curve describing the AFM heights of proteins of known molecular weight. Scrambled A␤ 1-42 peptide (rPeptide) was prepared following the same procedure as for the A␤O preparation.
Surface plasmon resonance. Surface plasmon resonance (SPR) experiments were performed using the Biacore X system (GE Healthcare) equipped with either a nitrilotriacetic acid (NTA) or CM5 sensor chip. The NTA chip was first charged with nickel ions and then uniformly covered with either PrP or STI1 bearing (His) 6 tags with SPR signal of ϳ10,000 resonance units (RU). The CM5 chip was prepared by a standard amine-coupling procedure (Fischer, 2010) . All ligands were injected in 25 mM HEPES, 150 mM NaCl, and 10 mM imidazole, pH 7.0, at 5 l/min, and on-kinetics were registered for 6 min. After each injection, off-kinetics were followed for 2 min. The chip surface was regenerated between injections by a short injection of 10 mM HCl. SPR curves for STI1 and A␤O binding to PrP were analyzed using a simple bimolecular binding model with GraphPad Software Prism linear (for initial binding rates), exponential decay (for off-kinetics), and "one-site binding" (to determine RU max and K D from the Langmuir equation for the STI1-PrP complex) regressions (Balducci et al., 2010) .
A␤O binding to cells. HEK293T cells were transfected with pHsensitive GFP-PrP C vector (pHFP-PrP C ) using a modified calcium phosphate method as described previously (Caetano et al., 2011) . pHFPPrP C was generated on the basis of pEGFP-PrP C vector (Lee et al., 2001 ) with GFP nucleotide sequence exchanged for that of pHFP (pHluorin; Miesenbock et al., 1998) . Fluorescent A␤Os were prepared from HiLyte Fluor 555-tagged A␤ 1-42 (Anaspec) following the procedure described above. Three hundred nanomolar HiLyte Fluor 555-A␤Os alone or mixed with 500 nM STI1 or 1000 nM TPR2A were added to cultures for 15 min, after which cells were washed with Krebs-Ringer-HEPES (KRH) buffer (in mM: 50 HEPES, 115 NaCl, 5.9 KCl, 1 MgCl 2 , 2 CaCl 2 , and 10 glucose, pH 7.4) and immediately imaged on a LSM510 confocal microscope (Carl Zeiss) equipped with a 63ϫ/1.4 numerical aperture (NA) oil-immersion objective. Data were collected from at least eight images taken for each treatment in three independent experiments. Bound HiLyte Fluor 555-A␤O was quantified for at least 20 cells for each experimental condition as mean fluorescence per cell area and normalized to nontransfected cells using NIH ImageJ software.
Primary cultures of hippocampal neurons from E17 mouse embryos were obtained as described previously . Neuronal cultures hereafter were derived from embryos of either sex. Cultures were maintained on poly-lysine-coated coverslips in Neurobasal medium with 2% B-27 supplement (Invitrogen). On day 4, cytosine arabinoside (2 M; Sigma) was added to prevent astrocyte growth. Half of the culture medium was changed every 2-3 days. On day 15, neurons were treated for 15 min with 200 nM A␤O alone or mixed with 500 nM STI1, washed with KRH buffer (in mM: 125 NaCl, 5 KCl, 5 HEPES, 2.6 MgSO 4 , and 10 glucose, pH 7.2). For ␥-tubulin and A␤O immunostaining, cells were fixed with 4% paraformaldehyde for 20 min, permeabilized with 0.5% Triton X-100 in PBS for 5 min, and blocked with 5% BSA (Sigma) in PBS for 1 h. After that, coverslips were incubated with anti-␥-tubulin (1:500; Abcam) and 6E10 (against amyloid-␤ 1-16 epitope; 1:350; Covance) antibodies overnight at 4°C, followed by secondary Alexa Fluor-488 (for ␥-tubulin) and Alexa Fluor-633 (for A␤O) antibodies (Invitrogen) for 1 h at 4°C. For colocalization analysis, the PrP antibody 8H4 (epitope 145-180; Abcam) and 6E10 antibodies were labeled with Alexa Fluor-488 and Alexa Fluor-633, respectively, using Zenon Mouse Labeling Kit (Invitrogen). Briefly, 1 g of each primary antibody was incubated at room temperature for 5 min with 5 l of the corresponding Zenon coupling reagent, after which the reaction was stopped by 5 min incubation with the blocking reagent. Labeled antibodies were diluted immediately in KRH buffer (1:350 for both antibodies), added to neurons treated with A␤O, A␤O/STI1, or vehicle, as described above, and incubated for 30 min at 37°C. Subsequently, cultures were washed with KRH buffer and imaged on an LSM510 confocal microscope equipped with a 63ϫ/1.4 NA oil-immersion objective or a SP5 II confocal microscope (Leica) equipped with a 63ϫ/1.47 NA oil-immersion objective. A␤Os, ␥-tubulin, and PrP C were quantified in at least three independent experiments. At least five Z-stack images were taken randomly from each coverslip representing a single treatment of neurons derived from a single embryo, and the corresponding fluorescence was integrated using NIH ImageJ software. Neurites from at least 20 cells were analyzed with cell bodies excluded from the quantification. A␤O-PrP C colocalization was determined as percentage of A␤O fluorescence volume colocalized with PrP C fluorescence using the NIH ImageJ colocalization plug-in.
Expression of synaptophysin. For these experiments, primary cultured hippocampal neurons were obtained as indicated previously . Cytosine ␤-D-arabinofuranoside at 1 M was added on day 2, and cultures were maintained with no media replacement. On day 20, cells that were preincubated with or without 100 nM STI1 for 30 min and were treated with 500 nM A␤O for 1 or 4 h unless otherwise indicated. For Western blots, cells were lysed in RIPA buffer (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) and analyzed by SDS-PAGE, followed by transfer to PVDF membrane and blotting with anti-synaptophysin (1:10,000; Santa Cruz Biotechnologies) and anti-GAPDH (1:1000; Sigma) antibodies. For immunofluorescence, cells were fixed with 4% paraformaldehyde for 20 min, permeabilized with 0.2% Triton X-100 in PBS for 5 min, and blocked with 5% BSA (Sigma) in PBS for 1 h. Anti-synaptophysin (1:100; Santa Cruz Biotechnologies) diluted in 1% BSA in PBS was added for 1 h, followed by anti-mouse Alexa Fluor-488 (1:1000; Invitrogen) for 1 h. Twenty images were analyzed per experiment with the NIH ImageJ histogram tool in at least three independent experiments for each experimental treatment, using a Nikon TE2000 microscope in epifluorescence mode. Images taken from cells labeled with secondary antibody only were used to set the threshold for the experiment. Cell bodies were excluded from the analysis.
Electrophysiology in hippocampal tissue slices. Field EPSPs (fEPSPs) were recorded from hippocampal slices derived from wild-type mice that were between 21-and 30 d-old as described previously (Martyn et al., 2012) . Slices were pretreated for 15-30 min with or without 0.5 or 1 M STI1, followed by 30 -60 min treatment with vehicle or 1 M A␤O. No difference was observed between these two time points and protein concentrations used, and, therefore, the results of these experiments were pooled together.
Cell death and viability assays for A␤O. Ϫ/Ϫ mice were prepared as described above. Primary hippocampal neurons were treated with staurosporine (50 nM) in the presence or absence of 1 M STI1 for 16 h as described previously . The cell death assay was performed using LIVE/DEAD Viability/Cytotoxicity Kit as described above. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay (Sigma) was conducted according to the protocol of the manufacturer. MTT stock solution (5 mg/ml) was added to hippocampal neurons as 1 ⁄10 of the culture medium volume and incubated for 4 h. After that, the medium was removed, and cells were solubilized with isopropanol/0.1 N HCl, after which absorbance of reduced dye was measured at 570 nm with background subtraction at 650 nm.
Calcium signaling. Primary hippocampal neurons were obtained as described for experiments with A␤O binding, and calcium imaging was performed as described previously , by loading neurons with either 10 M fura-2 AM for 40 min or 5 M Fluo-4 AM (Invitrogen) for 30 min at 37°C in Neurobasal medium supplemented with 1 mM CaCl 2 . For fura-2 AM experiments, data acquisition was performed using a DMI6000 B microscope (Leica) equipped with a 40ϫ/0.75 NA dry objective and 340 nm/380 nm (excitation) and 510 nm (emission) filters. Fluorescence ratio (340/380) was normalized using Leica AF6000 software. For Fluo-4 AM, data acquisition was performed on an LSM-510 confocal microscope with excitation at 488 nm and emission at 505-530 nm. Fluorescence was normalized as F 1 /F 0 (in which F 1 is maximal fluorescence and F 0 is basal fluorescence). For each experimental condition, at least three different neuronal cultures from independent pups were used, and 30 -40 cells were analyzed.
Human postmortem brain tissue. Parietal cortical tissues from age-and sex-matched controls (n ϭ 6, 3 females and 3 males) and AD-affected individuals (n ϭ 6, 3 females and 3 males) were provided by the Institute for Brain Aging and Dementia Tissue Repository/University of California, Irvine. AD diagnosis was confirmed by pathological and clinical criteria (McKhann et al., 1984; Khachaturian, 1985; Michalski and Fahnestock, 2003) . Cortical samples were homogenized in RIPA buffer supplemented with protease inhibitor cocktail III (Calbiochem). STI1 levels were analyzed by SDS-PAGE, followed by Western blot analysis with anti-recombinant mouse STI1 antibody raised in rabbits (Zanata et al., 2002; ; purified IgG, 0.2 g/ml, generated by Bethyl Laboratories) using ␤-actin levels as a control.
Mouse brain tissue. Cortical tissues from APPswe/PS1dE9 or wild-type control male mice were collected and homogenized in RIPA buffer as described above. STI1 levels were analyzed by SDS-PAGE, followed by Western blot analysis with rabbit anti-STI1 antibody (Zanata et al., 2002; Beraldo et al., 2013) using ␤-actin levels as a control. (Zanata et al., 2002) . To determine whether binding of these two PrP C ligands can occur simultaneously or whether they are mutually exclusive, we used SPR. We optimized standard procedures to obtain highly pure recombinant proteins (Ͼ95% according to SDS-PAGE analysis; Fig. 1A ) and to produce well defined A␤Os with substantial presence of low-order oligomers (Townsend et al., 2006; Hung et al., 2008; Larson et al., 2012; Figueiredo et al., 2013) . Western blot analysis of A␤O preparations showed 5-10% low-molecular-weight oligomers (2-, 3-, 4-mers) along with small amounts of higher-molecular-weight (HMW) components but no fibrils (Fig. 1B) . Importantly, the size-exclusion chromatography profile of these oligomers was similar to that of AD brain-derived amyloid-␤ species (Larson et al., 2012) and contained peaks corresponding to monomers, dimers, and trimers, with small amounts of HMW A␤O (Fig. 1C) . AFM analysis confirmed the abundance of low-order oligomers in our A␤O prep- aration, represented as 0.3-1 nm high round dots and a small amount of larger dots with their height (Ͼ1 nm) corresponding to HMW A␤O (Fig. 1D ). In addition, CD measurements demonstrated ␤-sheet structure in oligomer preparations and showed characteristic spectra for recombinant PrP (Ostapchenko et al., 2008) and STI1 (Romano et al., 2009; Fig. 1E) .
Results
STI1 prevents A␤O binding to PrP
Initial experiments demonstrated that A␤Os bind specifically to PrP in a dose-dependent manner (Fig. 1 F, G) . We used a simple bimolecular binding model to analyze SPR data and estimate kinetic constants of A␤O-PrP binding. Considering that dimers and trimers, the main PrP-binding species in this preparation, represent ϳ9% of the A␤Os in our preparation, we estimated K D ϭ 15 nM, with k on ϭ 3500 M Ϫ1 s Ϫ1 and k off ϭ 5.4 ϫ 10 Ϫ5 s Ϫ1 , which is consistent with previous studies (Balducci et al., 2010) . Of note, approximating off-kinetics with exponential decay gave a high error estimate in the k off measurement (ϳ50%), probably attributable to the fact that SPR signal noise and thermal drift magnitude were of the same order as the total SPR signal change during off-kinetics. Consequently, the calculated K D , as k off /k on , fell in the range of 7-30 nM. PrP lacking the N-terminal region ] was unable to interact with A␤Os (Fig. 1F ) . As a control, scrambled A␤ did not bind to full-length PrP (Fig. 1G) .
Recombinant STI1 impaired the binding of A␤Os to immobilized PrP with an IC 50 of ϳ70 nM (Fig. 1H ) . To ensure absence of nonspecific effects, we determined the binding of A␤Os premixed with either lipopolysaccharide (amount equivalent to that present in 500 nM recombinant STI1; Fig. 1I ) or an irrelevant protein (500 nM lysozyme; Fig. 1J ) to PrP. Neither of them altered A␤O binding to PrP. STI1 showed dose-dependent binding to PrP (Fig. 1K ) with K D ϭ 550 Ϯ 150 nM, k on ϭ 2.0 Ϯ 0.6 ϫ 10 5 M Ϫ1 s Ϫ1 , and k off ϭ 11.0 Ϯ 0.6 ϫ 10 Ϫ2 s Ϫ1 . The measured K D value is in the same order of magnitude of values determined using different methodologies (Zanata et al., 2002; Romano et al., 2009 ). A␤Os did not interact directly with STI1, although STI1 was able to interact with Hsp90 as a positive control under the same conditions (Fig. 1L) . The TPR2A domain of STI1 (containing PrP C binding motif amino acids 230 -245) decreased binding of A␤O to PrP (IC 50 of ϳ300 nM), whereas TPR2A⌬ 230 -245 , which lacks the PrP binding site, had no effect (Fig. 1M ) . Together, these results suggest that STI1 interferes with A␤O-PrP binding by impairing A␤O binding to PrP and not because of a direct interaction between STI1 and A␤O.
STI1 prevents A␤O binding to cells expressing PrP C
To investigate whether STI1 affects A␤O binding to PrP C on membranes of living cells, we initially used HEK293T cells. A␤Os bound only marginally to nontransfected cells, whereas HEK293T cells expressing pHFP-PrP C displayed abundant coating with A␤Os ( Fig. 2 A, B) . In the presence of 500 nM STI1, A␤O binding to pHFP-PrP C -transfected HEK293T cells was significantly decreased (Fig. 2 A, B) . TPR2A (1 M) also decreased A␤O binding to cells (Fig. 2 A, B) .
In cultured hippocampal neurons, A␤O binding showed a punctate pattern mainly localized to neurites (Fig. 3 A, C) as described previously (De Felice et al., 2007 . As observed in HEK293T cells, A␤O binding to hippocampal neurons in culture was significantly decreased by STI1 when compared with cells treated with vehicle (Fig. 3A-D) . Additionally, colocalization analysis indicated that ϳ50% of A␤O puncta were colocalized with PrP C (Fig. 3C,D) . In the presence of STI1, colocalization between A␤O puncta and PrP C was significantly decreased in hippocampal neurons (Fig. 3C,D) .
STI1 prevents A␤O-induced synaptic loss
A␤O treatment of human brain tissue downregulates several genes involved in synaptic transmission, including synaptophysin . Moreover, A␤Os elicit PrP Cdependent synaptic loss (Um et al., 2012) . Treatment of hippocampal neurons in culture with A␤Os for 60 min led to a decrease in synaptophysin levels ( Fig. 4A-C) . In contrast, exposure of hippocampal neurons to STI1 (100 nM) increased the levels of synaptophysin (Fig. 4 B, C) . In the presence of STI1, the toxic effect of A␤Os on synaptophysin levels was prevented (Fig.  4 B, C) . Importantly, neither A␤O or STI1 altered the levels of synaptophysin in hippocampal neurons cultured from Prnp Ϫ/Ϫ embryos (Fig. 4D) , indicating that these effects of A␤Os and STI1 depend on the presence of PrP C . (Fig. 5 A, B) . When slices were previously treated with STI1 (0.5-1 M), before being exposed to A␤Os (1 M), no decrease in LTP was observed, suggesting that treatment with STI1 prevents A␤O-induced LTP inhibition (Fig. 5C,D) . Interleaved recordings from control slices treated with A␤Os alone confirmed the neurotoxic potency of A␤O in these experiments, whereas STI1 alone did not modify LTP (data not shown).
STI1 rescues A␤O-induced inhibition of LTP in hippocampal slices
STI1 protects neurons against cellular injury induced by A␤O
It has been shown that A␤Os cause neuronal cell death in a PrP Cdependent manner (Resenberger et al., 2011; Kudo et al., 2012) . Corroborating this observation, we showed that wild-type but not Prnp Ϫ/Ϫ cultured hippocampal neurons displayed decreased viability, measured using the LIVE/DEAD Viability/Cytotoxicity assay, when exposed to 1 M A␤O for 48 h (Fig. 6A) . Of note, incubation of A␤Os in culture medium did not produce measurable amounts of fibrils or prefibrillar aggregates (Fig. 1B) , arguing that the observed toxicity is caused by low-molecular-weight A␤ species. Next, we checked whether levels of endogenous STI1 could influence the neurotoxic effect of A␤Os. STI1 Ϫ/ϩ neurons, shown previously to have 50% of wild-type STI1 protein levels , presented increased sensitivity to A␤O exposure (Fig. 6B-D) . Treatment of cultured neurons with STI1 prevented the toxic effects of A␤Os in both STI1 mutant and wild-type neurons (Fig. 6 B, D) . Neither STI1 by itself nor scrambled A␤ had any effect on neuronal viability (Fig. 6 B, D) . More- over, treatment of cultured neurons with TPR2A, the PrP C binding domain of STI1, also decreased the toxicity of A␤Os (Fig. 6E) . We also used LDH release as an indicator of cell death. Treatment with recombinant STI1 rescued neuronal death induced by A␤Os in both genotypes, confirming the results obtained with the LIVE/DEAD Viability/Cytotoxicity assay (Fig. 6F ) . In these experiments A␤O-induced LDH release appeared higher in STI1 Ϫ/ϩ neurons, but this difference failed to reach statistical significance (Fig.  6F ) . Together, our results indicate that STI1 decreases the binding of A␤Os to PrP C and prevents several toxic activities of A␤Os in hippocampal neurons.
STI1 induces intracellular Ca
2؉ increase and neuronal protection via ␣7nAChRs
We demonstrated previously that PrP C forms a biochemical and functional complex with ␣7nAChRs and that signaling and neuronal protection by STI1 was blocked by ␣-bungarotoxin, a selective ␣7nAChR-specific antagonist . A␤ has been shown to interact with ␣7nAChRs (Wang et al., 2000; Magdesian et al., 2005; Snyder et al., 2005) , which is thought to play an important role in AD (Hernandez and Dineley, 2012) . To test whether neuroprotection by STI1 might involve ␣7nAChRs, we cultured neurons from ␣7nAChR Ϫ/Ϫ mice and investigated the effect of STI1. We used neurons labeled with either fura-2 or Fluo-4 in independent experiments and found that Ca 2ϩ increase induced by STI1 was abolished in ␣7nAChR Ϫ/Ϫ neurons ( Fig. 7A-E) . Moreover, the TPR2A peptide also increased intracellular Ca 2ϩ in an ␣7nAChR-dependent way. Neuroprotection by STI1 against apoptosis induced by staurosporine (100 nM) was observed in wild-type neurons but not in ␣7nAChR Ϫ/Ϫ neurons, as determined by either the MTT reduction assay or the LIVE/DEAD Viability/Cytotoxicity assay (Fig.  7 F, G) . Similarly to wild-type neurons, A␤Os induced ϳ15-20% increase in cell death in ␣7nAChR Ϫ/Ϫ neurons; surprisingly, however, addition of STI1 did not rescue those neurons from A␤O-induced cell death (Fig. 7H ) . Of note, ␣7nAChR Ϫ/Ϫ neuronal cultures showed an increased background level of cell death [ϳ40 vs ϳ20% for wild-type neurons (Fig. 6B) ], suggesting that expression of ␣7nAChR is important for cell viability in neuronal cultures.
STI1 levels are increased in AD
STI1 is part of the cellular stress response, and we showed recently that STI1 knock-out cells are less resilient to stress . Moreover, network analysis suggests that STIP1, the STI1 gene, may be a critical biological node for regulation of the unfolded protein response in AD cerebral cortex (Zhang et al., 2013) . To determine whether STI1 levels change in AD, we fist performed analysis of the APPswe/PS1dE9 transgenic mouse model. These experiments revealed a 50% increase in cortical STI1 levels in 12-month-old APPswe/PS1dE9 but not in 9-month-old mice compared with wild-type controls (Fig.  8 A, B) . Importantly, STI1 levels were also increased in AD brains when compared with age-matched controls (cohorts described in Table 1 ; Michalski and Fahnestock, 2003;  Fig. 8C ).
Discussion
Here we show that the PrP C ligand STI1 prevents deficits of synaptic plasticity and increased neuronal death induced by toxic A␤O species. Mechanistically, both interference with A␤O binding to neurons and ␣7nAChR activation play a role in neuroprotection induced by STI1. Our data also demonstrate that STI1 levels are increased in AD. Although the biological significance of this change in STI1 levels is not understood, it is possible that, without this compensatory response, toxic effects of A␤Os could be more prominent. These results open a novel avenue in AD research indicating that endogenous PrP C ligands can regulate toxicity by A␤Os. ϩ/ϩ and STI1 Ϫ/ϩ neuronal cultures after 48 h treatment with 1 M A␤Os, 1 M STI1, or their mix. At least five independent experiments were done for each genotype and condition. Experiments with different genotypes were analyzed by two-way ANOVA, followed by Bonferroni's post hoc test, and within the same genotype by one-way ANOVA, followed by Tukey's post hoc test. *p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ 0.001. Resenberger et al., 2011; Kudo et al., 2012; Um et al., 2012) . We used well characterized synthetic A␤Os (Fig. 1) to mimic the effects of toxic AD-related A␤ species. In our conditions, A␤O preparations typically contained ϳ7% trimers and ϳ2% dimers, in addition to tetramers and small levels of higher-order oligomers. Dimers and trimers are thought to be among the most toxic assemblies of A␤ (Townsend et al., 2006; Hung et al., 2008; Figueiredo et al., 2013) and have been shown to bind PrP C and to induce PrP C -dependent toxic effects (Larson et al., 2012) .
STI1 interferes with the A␤O-PrP
We confirmed the specificity of A␤O binding to purified PrP using SPR and also demonstrated that expression of PrP C in cells increased A␤O binding substantially. These results are consistent with several other publications showing interaction between A␤Os from different sources and PrP C both in vitro and in vivo (Laurén et al., 2009; Balducci et al., 2010; Chen et al., 2010; Kessels et al., 2010; Larson et al., 2012) . The A␤O-PrP C complex is poorly understood at the molecular and structural levels, and its formation, based on SPR kinetic curves, is not likely to be a one-step process. It appears to start with a relatively slow binding phase with k on of just 3500 M Ϫ1 s Ϫ1 , but then the two proteins associate tightly (k off of ϳ5 ϫ 10 Ϫ5 s Ϫ1 ), resulting in a high-affinity complex with K D of ϳ15 nM. Therefore, it is reasonable to hypothesize that binding occurs in more than one step, and the initial lower-affinity interaction is followed by a rearrangement step leading to formation of a strong complex. Of note, the K D for on-chip STI1 binding to PrP (550 nM) is higher than that observed for A␤Os, but its initial binding rate (k on ϭ 2 ϫ 10 5 M Ϫ1 s
Ϫ1
) is much faster, suggesting the possibility that STI1 could prevent the formation of this hypothetical initial low-affinity A␤O-PrP C complex. The molecular mechanism of this competition is probably related to the adjacent binding sites for STI1 and A␤O on the PrP C N-terminal domain. Thus, binding of STI1 (or the TPR2A domain of STI1, which contains the motif responsible for STI1 binding to PrP) to amino acid residues 113-128 on PrP possibly makes adjacent regions sterically unavailable to other ligands. This could explain why TPR2A alone, a less bulky molecule compared with STI1, shows weaker inhibition of A␤O binding to PrP. Alternatively, conformational changes on PrP induced by STI1 (Romano et al., 2009 ) could also affect the interactions between PrP and A␤O.
STI1 prevents toxic effects of A␤Os
Interaction of A␤Os with neurons leads to multiple neurotoxic effects, and although the underlying mechanisms have not been completely delineated, NMDA receptor-mediated excitotoxicity and abnormal activation of Fyn kinase have been implicated (Larson et al., 2012; Um et al., 2012) . Abnormal activation of NMDAR and Fyn kinase seem to connect toxic actions of A␤Os to altered Tau function (Ittner et al., 2010) . PrP C seems to interact directly with NMDA receptors and to regulate their desensitization by providing a source of copper, which can be disrupted by increased A␤ 1-42 (You et al., 2012) . In agreement with these toxic effects, A␤Os disrupt synaptic plasticity, including LTP, which has been shown to be an effect dependent on PrP Ϫ/Ϫ neuronal cultures after 48 h treatment with 1 M A␤O, 1 M STI1, or their mix, measured by LIVE/DEAD Viability/Cytotoxicity assay. Neuronal cultures were obtained from 13 independent embryos, and the data were analyzed by one-way ANOVA with Tukey's post hoc test. ***p Ͻ 0.0001. man cortical slices . Conversely, STI1 increased immunoreactivity for synaptophysin, consistent with its known effect of increasing neuronal protein synthesis . Additionally, STI1 was able to protect hippocampal neurons from the toxic effect of A␤Os on synaptophysin levels. Importantly, the effects of both STI1 and A␤Os on synaptophysin levels were lost in cultures from PrP C -null mice, indicating that PrP C is involved in these signaling pathways. Moreover, STI1 prevented inhibition of LTP induced by A␤Os. These results suggest that increased extracellular levels of STI1, a PrP C ligand that is secreted by astrocytes (Beraldo et al., 2013; Hajj et al., 2013), can mitigate A␤O-mediated synaptic toxicity.
We also showed that neurons haploinsufficient for STI1 are more sensitive to A␤O-induced cell death, a result consistent with our recent findings that cells are less resilient in the absence of STI1 . Hence, the differential expression of STI1 in AD brains may have physiological significance. Interestingly, flies harboring an STI1 mutation showed increased toxicity in a model of tauopathy (Ambegaokar and Jackson, 2011) , suggesting that STI1 may be a critical regulator of distinct pathological signatures in AD. The increased neuronal death induced by A␤Os in STI1-mutant hippocampal neurons could be prevented by extracellular recombinant STI1. We showed previously that extracellular recombinant STI1 reproduces the effect of secreted STI1 (Caetano et al., 2008) . Moreover, the TPR2A STI1 domain, which lacks cochaperone activity because it is unable to bind both Hsp90 and Hsp70 (Brinker et al., 2002) , could also prevent A␤O-mediated neuronal death, suggesting that the neuroprotective effects of STI1 may not be related to a cochaperone mechanism.
Mechanism for prevention of A␤O-mediated toxicity
Although STI1 decreases the binding of A␤Os to PrP C in vitro, it is also possible that the protein could regulate A␤O-mediated toxicity by activating neuroprotective signaling pathways (Lopes et al., 2005; Caetano et al., 2008; . We found that STI1-mediated Ca 2ϩ influx was abolished in neurons from ␣7nAChR-null mice and that STI1-mediated neuroprotection is impaired in these mutants. Importantly, prevention of A␤O-induced neuronal death by STI1 was not observed in ␣7nAChR-null neurons. This result suggests that, in the presence of STI1, residual A␤O complexes with PrP C or other targets may still initiate toxic responses. Nonetheless, STI1 activation of the PrP C /␣7nAChR pathway seems to prevent these effects. Together, these results argue that decrease of A␤O interaction with PrP C in addition to activation of ␣7nAChR-mediated neuroprotection pathways may participate in the effects of STI1.
Our work is consistent with previous studies showing neuroprotective roles of ␣7nAChR in AD Hernandez et al., 2010; Shen et al., 2010) . Indeed, A␤ actions via ␣7 nAChRs may also affect hippocampal LTP (Gu and Yakel, 2011) , and genetic depletion of ␣7 nAChRs in an early-stage AD mouse model exacerbated cognitive deficits and septohippocampal pathology (Hernandez et al., 2010) . Interestingly, higher concentrations or chronic exposure to A␤O appears to corrupt ␣7nAChR function, which can be prevented by intervening small molecules or by genetic depletion of ␣7nAChR (Dziewczapolski et al., 2009) . It remains to be determined whether biasing signaling via PrP C /␣7nAChR by further increasing STI1 levels could be used to prevent the toxic actions of A␤Os in vivo.
Conclusion
Our studies suggest the possibility that STI1 may influence toxic responses to A␤ oligomers in AD. Increased levels of STI1 ob- Samples were taken from control and AD postmortem brains with indicated postmortem interval (PMI, hours) and age and sex matched in pairs (except for pair 6) for Western blot analysis of STI1 levels.
served in AD brain may exert a protective role, although this obviously cannot prevent toxicity in advanced disease. It is possible that higher levels of STI1 are part of a compensatory response that may mitigate toxicity. Future experiments using tissue-specific elimination of STI1 may help to clarify this issue. STI1 is a cochaperone known to interact with Hsp90 and Hsp70 to facilitate client transfer (Southworth and Agard, 2011) . Our experiments in neurons support the importance of extracellular STI1 in protection against A␤O toxicity; however, we cannot completely exclude that intracellular STI1 may also participate in cellular resilience in this condition . Increased chaperone activity may also play a role in protection against prolonged A␤O exposure (Resenberger et al., 2012) , which induces oxidative stress (De Felice et al., 2007) and mitochondrial damage in neurons (Paula-Lima et al., 2011) , leading to increased load of misfolded proteins (Li et al., 2009 ). Interestingly, we showed recently that, after 9 months of age, APP/Ps1dE9 mice seem to present increased oxidative stress, revealed by increased PrP C ␤ processing (Ostapchenko et al., 2013) . Our present findings describe a novel neuroprotective role for the PrP C ligand STI1, which added to recent systems biology reports (Ambegaokar and Jackson, 2011; Zhang et al., 2013) , implicates STI1 in distinct aspects of AD.
